Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Sell
28
BDX Quote, Financials, Valuation and Earnings
Last price:
$169.74
Seasonality move
:
-0.1%
Day range:
$167.50 - $170.64
52-week range:
$163.33 - $251.99
Dividend yield:
2.4%
P/E ratio:
32.39x
P/S ratio:
2.36x
P/B ratio:
1.93x
Volume:
3.1M
Avg. volume:
2.9M
1-year change:
-28.78%
Market cap:
$48.6B
Revenue:
$20.2B
EPS (TTM):
$5.24
Analysts' Opinion
-
Consensus RatingBecton Dickinson & has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 11 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $221.75, Becton Dickinson & has an estimated upside of 30.66% from its current price of $169.72.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $172.00 representing 100% downside risk from its current price of $169.72.
Fair Value
-
According to the consensus of 15 analysts, Becton Dickinson & has 30.66% upside to fair value with a price target of $221.75 per share.
BDX vs. S&P 500
-
Over the past 5 trading days, Becton Dickinson & has underperformed the S&P 500 by -2.17% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Becton Dickinson & does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Becton Dickinson & has grown year-over-year revenues for 9 quarters straight. In the most recent quarter Becton Dickinson & reported revenues of $5.3B.
Earnings Growth
-
Becton Dickinson & earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Becton Dickinson & reported earnings per share of $1.07.
Enterprise value:
67.2B
EV / Invested capital:
1.51x
Price / LTM sales:
2.36x
EV / EBIT:
29.47x
EV / Revenue:
3.22x
PEG ratio (5yr expected):
2.10x
EV / Free cash flow:
25.97x
Price / Operating cash flow:
19.01x
Enterprise value / EBITDA:
14.46x
Gross Profit (TTM):
$9.3B
Return On Assets:
2.71%
Net Income Margin (TTM):
7.18%
Return On Equity:
5.86%
Return On Invested Capital:
3.35%
Operating Margin:
12.08%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $18.8B | $19.7B | $20.9B | $5B | $5.3B | |
| Gross Profit | $8.5B | $8.1B | $9.3B | $2.3B | $2.3B | |
| Operating Income | $2.5B | $2.5B | $2.7B | $835M | $637M | |
| EBITDA | $4.4B | $4.4B | $4.7B | $1.3B | $1.1B | |
| Diluted EPS | $5.33 | $4.54 | $5.24 | $1.85 | $1.07 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $10B | $10.2B | $9.6B | $10.3B | $8.7B | |
| Total Assets | $54.9B | $54.8B | $54.4B | $54.2B | $54.5B | |
| Current Liabilities | $5.4B | $6.7B | $7.3B | $7.3B | $7.7B | |
| Total Liabilities | $30.1B | $30.3B | $28.7B | $28.5B | $29.2B | |
| Total Equity | $24.8B | $24.5B | $25.7B | $25.6B | $25.2B | |
| Total Debt | $17.7B | $18.6B | $18.2B | $18B | $19.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.1B | $3.8B | $3.3B | $515M | $164M | |
| Cash From Investing | -$2.8B | -$1.5B | -$4.2B | -$1.1B | -$192M | |
| Cash From Financing | -$561M | -$1.9B | -$724M | $1.7B | -$39M | |
| Free Cash Flow | $1.1B | $3B | $2.6B | $381M | $35M | |
BDX
Sector
Market Cap
$48.6B
$32.8M
Price % of 52-Week High
67.35%
46.28%
Dividend Yield
2.4%
0%
Shareholder Yield
1.92%
-0.74%
1-Year Price Total Return
-28.78%
-35.38%
Beta (5-Year)
0.251
0.632
Dividend yield:
2.4%
Annualized payout:
$3.80
Payout ratio:
76.77%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$171.02
200-day SMA
Sell
Level
$218.38
Bollinger Bands (100)
Sell
Level
177.38 - 230.72
Chaikin Money Flow
Buy
Level
615.7M
20-day SMA
Sell
Level
$171.79
Relative Strength Index (RSI14)
Sell
Level
40.12
ADX Line
Sell
Level
21.91
Williams %R
Neutral
Level
-74.8584
50-day SMA
Sell
Level
$180.23
MACD (12, 26)
Sell
Level
-2.88
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
303.5M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.2563)
Buy
CA Score
(Annual)
Level (-0.2538)
Buy
Beneish M-Score
(Annual)
Level (-2.5661)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-1.0561)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
Stock Forecast FAQ
In the current month, BDX has received 4 Buy ratings 11 Hold ratings, and 0 Sell ratings. The BDX average analyst price target in the past 3 months is $221.75.
-
Where Will Becton Dickinson & Stock Be In 1 Year?
According to analysts, the consensus estimate is that Becton Dickinson & share price will rise to $221.75 per share over the next 12 months.
-
What Do Analysts Say About Becton Dickinson &?
Analysts are divided on their view about Becton Dickinson & share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Becton Dickinson & is a Sell and believe this share price will drop from its current level to $172.00.
-
What Is Becton Dickinson &'s Price Target?
The price target for Becton Dickinson & over the next 1-year time period is forecast to be $221.75 according to 15 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 11 analysts rate the stock a Hold.
-
Is BDX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Becton Dickinson & is a Hold. 11 of 15 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BDX?
You can purchase shares of Becton Dickinson & via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Becton Dickinson & shares.
-
What Is The Becton Dickinson & Share Price Today?
Becton Dickinson & was last trading at $169.74 per share. This represents the most recent stock quote for Becton Dickinson &. Yesterday, Becton Dickinson & closed at $169.72 per share.
-
How To Buy Becton Dickinson & Stock Online?
In order to purchase Becton Dickinson & stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
88
CDTX alert for Jun 24
Cidara Therapeutics [CDTX] is up 113.42% over the past day.
Sell
46
HIMS alert for Jun 24
Hims & Hers Health [HIMS] is down 34.62% over the past day.
Sell
45
WGS alert for Jun 24
GeneDx Holdings [WGS] is up 18.69% over the past day.
